In patients with acyanotic congenital heart disease who develop clinically significant pulmonary hypertension (mean pulmonary artery pressure ≥25 mm Hg at rest with symptoms or right‑ventricular strain), what pulmonary vasodilator therapy is recommended, including first‑line agents, dosing, and monitoring?

Pulmonary Vasodilators in Acyanotic Congenital Heart Disease

In acyanotic congenital heart disease with clinically significant pulmonary hypertension, bosentan is the first-line pulmonary vasodilator therapy, particularly for patients with WHO functional class III symptoms and elevated pulmonary vascular resistance ≥3 Wood units. 1

Diagnostic Prerequisites Before Initiating Therapy

Before starting any pulmonary vasodilator, cardiac catheterization is mandatory to confirm:

• Mean pulmonary artery pressure ≥25 mmHg at rest
• Pulmonary vascular resistance >3 Wood units
• Pulmonary artery wedge pressure ≤15 mmHg (to exclude postcapillary pulmonary hypertension)
• Assessment of shunt direction and magnitude 1

This distinction is critical because postcapillary pulmonary hypertension (elevated left ventricular filling pressures) can cause pulmonary edema with vasodilator escalation if left ventricular dysfunction is underestimated 2.

First-Line Therapy: Endothelin Receptor Antagonists

Bosentan (Class I, Level A Evidence)

Bosentan is the only pulmonary vasodilator with Class I, Level A evidence for symptomatic adults with pulmonary arterial hypertension associated with congenital heart disease, specifically validated in patients with ASD or VSD 1.

Dosing:

• Initial: 62.5 mg twice daily for 4 weeks
• Maintenance: 125 mg twice daily

Monitoring requirements:

• Liver function tests monthly (risk of hepatotoxicity)
• Hemoglobin (risk of anemia)
• Pregnancy testing in women of childbearing age (teratogenic)

Extended Bosentan Indications (Class IIa, Level B-NR/C-EO)

Bosentan is reasonable for:

• Other shunt types (PDA, aortopulmonary window) 1
• Complex congenital heart lesions 1
• Patients with Down syndrome 1

Second-Line Therapy: Phosphodiesterase-5 Inhibitors

Sildenafil or Tadalafil (Class IIa, Level B-NR)

PDE-5 inhibitors are reasonable for symptomatic adults with Eisenmenger syndrome involving ASD, VSD, or great artery shunts 1.

Sildenafil dosing:

• 20 mg three times daily
• Can titrate to 40-80 mg three times daily based on response

Tadalafil dosing:

• 20-40 mg once daily

Monitoring:

• Blood pressure (risk of systemic hypotension)
• Visual changes (rare optic neuropathy)
• Avoid in patients taking nitrates

Combination Therapy Strategy

When to Escalate (Class IIa, Level B-R)

If symptomatic improvement does not occur with either bosentan or PDE-5 inhibitor monotherapy alone, combination therapy with both drug classes is reasonable 1.

The algorithmic approach:

1. Start with bosentan monotherapy
2. Reassess at 3-6 months with:
   • 6-minute walk distance
   • BNP/NT-proBNP levels
   • WHO functional class
   • Echocardiography for right ventricular function
3. If inadequate response → add PDE-5 inhibitor
4. If still inadequate → consider prostacyclin analogs or referral for advanced therapies

Alternative Agents

Riociguat (Soluble Guanylate Cyclase Stimulator)

For patients with persistent/recurrent PAH after correction of congenital heart disease, riociguat improved 6-minute walk distance by 39 meters and reduced pulmonary vascular resistance by 250 dyn·s/cm⁵ in clinical trials 3. However, riociguat should never be combined with PDE-5 inhibitors due to risk of severe hypotension.

Dosing:

• Initial: 1 mg three times daily
• Titrate by 0.5 mg increments every 2 weeks
• Maximum: 2.5 mg three times daily

Prostacyclin Analogs (Class IIa, Level C)

Consider for high-risk patients or those failing oral combination therapy:

• Epoprostenol (continuous IV infusion)
• Treprostinil (subcutaneous, IV, or inhaled)
• Iloprost (inhaled)

These require specialized pulmonary hypertension center management 4.

Critical Management Principles

Collaborative Care Requirement (Class I, Level B-NR)

Patients with pulmonary vascular resistance ≥2.5 Wood units must be assessed collaboratively by both an adult congenital heart disease cardiologist AND a pulmonary hypertension expert 1. These subspecialties have complementary but distinct knowledge bases essential for optimal outcomes.

Monitoring Protocol (Class I, Level C-EO)

Serial assessment should include:

• BNP or NT-proBNP levels
• 6-minute walk test
• Chest X-ray
• Echocardiography every 6-12 months
• Repeat cardiac catheterization within 3-12 months after therapy initiation or with clinical worsening 2, 1

Contraindications and Pitfalls

Calcium channel blockers should be avoided in patients with Eisenmenger syndrome (Class III, Level C) 4. Despite their use in idiopathic PAH, they can worsen outcomes in congenital heart disease-associated PAH.

Do not initiate PAH-targeted therapy without:

1. Confirming precapillary pulmonary hypertension by catheterization
2. Excluding elevated pulmonary capillary wedge pressure >15 mmHg
3. Ruling out other contributors (lung disease, chronic thromboembolic disease)

The risk of pulmonary edema is substantial if left ventricular diastolic dysfunction is present but unrecognized 2.

Shunt Closure Considerations

Mechanical interventions (shunt closure) may be considered as part of short-term management, but even modest residual PAH substantially determines long-term outcomes 1. Operability assessment requires:

• Pulmonary vascular resistance <3 Wood units (correctable)
• PVR 3-5 Wood units (case-by-case with vasoreactivity testing)
• PVR >5 Wood units (generally inoperable) 5, 6

Specific Subgroup: PAH After Defect Correction

For patients who develop PAH months to years after surgical repair, the clinical picture resembles idiopathic PAH 7. These patients should receive aggressive PAH-targeted therapy similar to idiopathic PAH, often requiring initial combination therapy or sequential escalation 8.

Emerging Therapies

Recent evidence suggests sotatercept (activin signaling inhibitor) may provide marked hemodynamic improvement in severe refractory PAH-CHD, reducing mean pulmonary artery pressure from 48 to 26 mmHg in case reports 9. However, this remains investigational with limited evidence in the congenital heart disease population.

The "treat and repair" strategy—initial medical therapy to improve PAH followed by surgical repair—represents a promising approach for patients with systemic-to-pulmonary shunts and borderline operability 5.